IDH1 Mutations Disrupt Blood, Brain, and Barriers

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2012 Sep 15

PMID 22975371

Citations 8

Authors

Alan H Shih

Ross L Levine

Affiliations

Soon will be listed here.

Abstract

The first two murine models of IDH1(R132H) mutation provide mechanistic insights into transformation. In hematopoietic cells, inhibition of TET2 and histone demethylases leads to epigenetic alterations and accumulation of hematopoietic precursors. In the central nervous system, inhibition of collagen and prolyl hydroxylases lead to altered microenvironment and defective angiogenesis.

Citing Articles

The genomics of acute myeloid leukemia in children.

Conneely S, Rau R Cancer Metastasis Rev. 2020; 39(1):189-209.

PMID: 31925603 PMC: 7324027. DOI: 10.1007/s10555-020-09846-1.

Vascular-endothelial response to IDH1 mutant fibrosarcoma secretome and metabolite: implications on cancer microenvironment.

Mao M, Leonardi D Am J Cancer Res. 2019; 9(1):122-133.

PMID: 30755816 PMC: 6356916.

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.

Romanidou O, Kotoula V, Fountzilas G Cancer Genomics Proteomics. 2018; 15(5):421-436.

PMID: 30194083 PMC: 6199574. DOI: 10.21873/cgp.20101.

Brain stem cells as the cell of origin in glioma.

Modrek A, Bayin N, Placantonakis D World J Stem Cells. 2014; 6(1):43-52.

PMID: 24567787 PMC: 3927013. DOI: 10.4252/wjsc.v6.i1.43.

5-hydroxymethylcytosine: a new insight into epigenetics in cancer.

Ye C, Li L Cancer Biol Ther. 2013; 15(1):10-5.

PMID: 24253310 PMC: 3938512. DOI: 10.4161/cbt.27144.